Resources

In part 5, the conclusion of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the necessity of including mental health care in overall diabetes care, but also the need to show insurance companies how mental health services can contribute.

Novo Nordisk requests approval for new type 2 treatment with heart benefits.

Too many highs and lows in glucose levels could be another reason that causes cardiovascular complications.

Maintaining a blood pressure below 130/80 mm Hg can eventually reduce the risk of having a repeat stroke, according to a recent study.

Woman, 43 years of age, PCOS, prediabetes, BMI 26, B/P 130/70, A1C 5.5%, Lipids, TC-156, HDL 52, Trig 76, LDL 84, mother of 3 children, visited today. She reports that her mother had PCOS, so was very carefully watching her as a child and adolescent hoping to prevent her from developing the complications of PCOS, such as infertility, obesity, type 2 diabetes, cardiovascular disease, and/or cancer later in life.

Treatment throughout pregnancy may reduce rate of miscarriage or preterm delivery.

CANVAS Program shows reduced heart events but increased risk of side effects.

Single episode of moderate/severe DKA in young children at diagnosis associated with lower cognitive scores, altered brain growth.

Other genetic markers—the “missing heritability": Collectively the confirmed T1DM risk loci account for approximately 70% of disease heritability, with around 40–50% being attributed to the HLA genes. These figures are well in excess of the 10–20% of heritability of other complex diseases that can be explained by genetic factors. Experience from GWAS suggests that overall disease risk is likely to be influenced by many genes, most having a weak biologic effect. This may be due to the subtle effects of risk alleles on gene function or the modest contribution of individual gene products to the biologic pathways involved in disease pathogenesis. None of the confirmed T1DM risk variants have complete penetrance and are therefore neither necessary nor sufficient for disease to develop. This makes it difficult to use genetic profiling to predict disease risk as T1DM can develop in the absence of susceptibility variants and does not always occur in subjects with known risk markers.

Metformin proposes therapeutic benefit for HFpEF treatment.